Blessing to the new series of articles under the health reform II- The new medical reform the pharmaceutical companies into four major errors Mo- (I).docVIP

 PAGE \* MERGEFORMAT 11 Blessing to the new series of articles under the health reform II: The new medical reform the pharmaceutical companies into four major errors Mo? (I) lt;lt;CPC Central Committee and State Council on Deepening the views of medical and health systemgt; “and” lt;recent focus on medical and health system implementation plan (2009-2011gt;gt; was 6 April 2009 and 7 pm. New healthcare reform plan proposed invest 850 billion within three years to achieve full coverage of basic medical insurance system of urban and rural residents, to effectively alleviate the “difficult and expensive, drug prices high” problem. It is a good thing benefits the country, the government is to build a harmonious society items of major institutional innovation, practical solution for the people, top people’s livelihood, major medical use of drugs, but pharmaceutical companies is a painful choice. On the occasion of the “new medical reform,” the first anniversary of the implementation, market research centers blessing to a market drawn. The results show: the new health reform is to bring hundreds of millions of people Full laughter, bring most of the pharmaceutical companies are helpless smile. There are two reasons : First of all, the face of health care, basic drugs, the new rural cooperative, a round of market expansion, “feast”, not every pharmaceutical companies are able to get the “invitation.” Secondly, the “catalog” system, so many pharmaceutical companies dilemma: not into the catalog, the future will lose the majority of the market space, enter the directory, the tender price will result in a significant reduction in profit margins. Is around the “directory” switch, or around the “consumer” switch? Is around the “products” turn or “brand” switch? Is around the “cost” turn around, or “demand” switch? ... ... See health care reform out of medical reform. Fu to believe that those who enter the directory of pharmaceutical companies does not necessarily